Several recent cases from the US Court of Appeals for the Federal Circuit offer guidance on navigating the §101 legal framework with respect to CRISPR patent claims, as Pat Carson and Mira Atanassova Mulvaney of Kirkland & Ellis report.
- Patenting polymorphs in Mexico 11-09-2018
- Mexico’s patent linkage system: current state, effects and flaws 06-09-2018
- LSIPR 50 2018: Robert Nelsen 05-09-2018
- Patenting microorganisms in Mexico 05-09-2018
- Medtech M&A: integration is key 04-09-2018
Latest americas news
Gene-editing company CRISPR Therapeutics has partnered with regenerative medicine-focused ViaCyte to focus on diabetes treatments.